Stock Traders Buy Large Volume of Tempus AI Call Options (NASDAQ:TEM)

Tempus AI, Inc. (NASDAQ:TEM) saw some unusual options trading on Tuesday. Stock investors bought 43,297 call options on the company. This is an increase of 601% compared to the average volume of 6,178 call options.

Analyst Ratings Changes

TEM has been the subject of several recent analyst reports. Loop Capital decreased their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Bank of America raised their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $56.36.

Tempus AI Trading Up 39.3 %

Shares of NASDAQ:TEM traded up $13.82 during trading on Tuesday, reaching $48.97. The stock had a trading volume of 19,011,556 shares, compared to its average volume of 4,943,078. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The stock has a fifty day simple moving average of $45.18 and a two-hundred day simple moving average of $47.27. Tempus AI has a 52 week low of $22.89 and a 52 week high of $79.49.

Insider Activity

In related news, major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the sale, the insider now directly owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew Polovin sold 51,504 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the sale, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. This represents a 17.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,300,761 shares of company stock valued at $51,271,197.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TEM. First Horizon Advisors Inc. acquired a new stake in Tempus AI in the 3rd quarter worth $30,000. FNY Investment Advisers LLC bought a new position in shares of Tempus AI during the 4th quarter worth about $67,000. Sandia Investment Management LP acquired a new stake in shares of Tempus AI during the 2nd quarter valued at about $136,000. Vestor Capital LLC bought a new stake in Tempus AI in the third quarter valued at about $153,000. Finally, Stifel Financial Corp acquired a new position in Tempus AI in the third quarter worth about $218,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.